The DOI matches its Crossref record; 300 of the 302 references it cites were found in a registry or an index.
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Open accessAbstract
The T lymphocyte, especially its capacity for antigen-directed cytotoxicity, has become a central focus for engaging the immune system in the fight against cancer. Basic science discoveries elucidating the molecular and cellular biology of the T cell have led to new strategies in this fight, including checkpoint blockade, adoptive cellular therapy and cancer vaccinology. This area of immunological research has been highly active for the past 50 years and is now enjoying unprecedented bench-to-bedside clinical success. Here, we provide a comprehensive historical and biological perspective regarding the advent and clinical implementation of cancer immunotherapeutics, with an emphasis on the fundamental importance of T lymphocyte regulation. We highlight clinical trials that demonstrate therapeutic efficacy and toxicities associated with each class of drug. Finally, we summarize emerging therapies and emphasize the yet to be elucidated questions and future promise within the field of cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Conversely, myeloid-specific overexpression of HIF-1α results in hyperinflammatory, M1-polarized macrophages associated with increased glycolysis, suggesting a link between HIF-1α and M1-polarization [63].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The possible contribution of the adaptive immune system in AD patients to reducing cancer incidence has not been studied (4,5).”
From Alzheimer's Disease–Associated Amyloid-β Precursor Protein Prevents Aging Stress–Induced Mitophagy and Fumarate Depletion to Improve Antitumor Immunity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“Typically, PD‐L1 or PD‐L2 are expressed on the surface of cancer cells or antigen‐presenting cells and transduce a signal for cooperation with PD‐1 expression on the cell surface of T lymphocytes to stimulate restraint signaling [272, 273].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [272]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Cited by
Sorted by citations
Items 601–700 of 1,006
Iwase, T., Blenman, K., Li, X., Reisenbichler, E., Seitz, R. S., Hout, D. R., Nielsen, T. J., Schweitzer, B. L., Bailey, D. B., Shen, Y., et al. (2021) · Cancers · doi:10.3390/cancers13194839 · Cited by 45
Metrangolo, V., Ploug, M., & Engelholm, L. H. (2021) · Cancers · doi:10.3390/cancers13215376 · Cited by 44
CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
Elmas, E., Saljoughian, N., Pereira, M. D. S. F., Tullius, B. P., Sorathia, K., Nakkula, R. J., Lee, D. A., & Kararoudi, M. N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.834002 · Cited by 47
Asemani, Y., Najafi, S., Ezzatifar, F., Zolbanin, N. M., & Jafari, R. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00808-4 · Cited by 45
Recent Advances of Emerging Spleen‐Targeting Nanovaccines for Immunotherapy
He, X., Wang, J., Tang, Y., Chiang, S. T., Han, T., Chen, Q., Qian, C., Shen, X., Li, R., & Ai, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300351 · Cited by 44
Deregulated transcription factors in the emerging cancer hallmarks
Hasan, A., Khan, N. A., Shahab Uddin, M. S., Khan, A. Q., & Steinhoff, M. S. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.12.001 · Cited by 45
Wang, B., Zhou, J., Li, R., Tang, D., Cao, Z., Xu, C., & Xiao, H. (2024) · Advanced Materials · doi:10.1002/adma.202311640 · Cited by 44
Zhang, T., Tai, Z., Miao, F., Zhang, X., Li, J., Zhu, Q., Wei, H., & Chen, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.033 · Cited by 47
Emerging trends and therapeutic applications of monoclonal antibodies
Ramaiah, M. J., Nalluri, H. P., Reddy, P. N., Sainath, S. B., Kumar, N. S. S., Sai Kiran, G. V. S. D., Dhiman, R., Chamarthy, S., Komaragiri, R. R., Manyam, R. R., et al. (2024) · Gene · doi:10.1016/j.gene.2024.148607 · Cited by 45
The Immune Endocannabinoid System of the Tumor Microenvironment
Kienzl, M., Kargl, J., & Schicho, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238929 · Cited by 47
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
de Jong, F. C., Rutten, V. C., Zuiverloon, T. C. M., & Theodorescu, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062800 · Cited by 44
The promise of bispecific antibodies: Clinical applications and challenges
Lim, S. M., Pyo, K., Soo, R. A., & Cho, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102240 · Cited by 45
Zaki, M. Y. W., Fathi, A. M., Samir, S., Eldafashi, N., William, K. Y., Nazmy, M., Fathy, M., Gill, U. S., & Shetty, S. (2022) · Cancers · doi:10.3390/cancers14051255 · Cited by 49
Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy
Li, J., Huang, L., Zhou, H., Shan, Y.-M., Chen, F., Lehto, V., Xu, W., Luo, L., & Yu, H. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00910-w · Cited by 44
Wang, J., Chen, C., Wang, L., Xie, M., Ge, X., Wu, S., He, Y., Mou, X., Ye, C., & Sun, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.872531 · Cited by 46
Peng, P., Lou, Y., Wang, S., Wang, J., Zhang, Z., Du, P., Zheng, J., Liu, P., & Xu, L. X. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005769 · Cited by 43
Tao, S., Liang, S., Zeng, T., & Yin, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043667 · Cited by 46
Liu, H., Gonzalez, D. D., Viswanath, D. I., Pol, R. V., Saunders, S. Z., Trani, N. D., Xu, Y., Zheng, J., Chen, S., Chua, C. Y. X., et al. (2023) · Advanced Science · doi:10.1002/advs.202206873 · Cited by 42
Zhang, B., Zhang, J., Li, Y., Li, N., Wang, Y., Jang, R., Xu, X., Li, R., Chen, Z., Duan, S., et al. (2023) · Advanced Materials · doi:10.1002/adma.202300171 · Cited by 43
Mohite, P. B., Yadav, V., Pandhare, R., Maitra, S., Saleh, F. M., Saleem, R. M., Al-malky, H. S., Kumarasamy, V., Subramaniyan, V., Abdel‐Daim, M. M., et al. (2024) · ACS Omega · doi:10.1021/acsomega.3c06501 · Cited by 47
Role of the gut microbiota in tumorigenesis and treatment
Liu, Q., Yang, Y., Pan, M., Yang, F., Yu, Y., & Qian, Z. (2024) · Theranostics · doi:10.7150/thno.91700 · Cited by 46
Zhou, X., Wang, G., Tian, C., Du, L., Prochownik, E. V., & Li, Y. (2024) · Nature Communications · doi:10.1038/s41467-024-50138-x · Cited by 47
Jurado, L. F., Daman, A. W., Li, Z., Ross, V. M. S., Nikolaou, K., Tran, K. A., Loutochin, O., McPherson, V. A., Prével, R., Tarancón, R., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.05.026 · Cited by 45
Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 55
Köhler, N., Ruess, D. A., Kesselring, R., & Zeiser, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.634435 · Cited by 45
Zafar, M. M., Rauf, Z., Sohail, A., Khan, A. R., Obaidullah, M., Khan, S. H., Lee, Y. S., & Khan, A. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102676 · Cited by 43
Harryvan, T. J., Visser, M., de Bruin, L., Plug, L. G., Griffioen, L., Mulder, A., van Veelen, P. A., van Noort, G. J. V. D. H., Jongsma, M. L. M., Meeuwsen, M. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003591 · Cited by 44
Aramini, B., Masciale, V., Arienti, C., Dominici, M., Stella, F., Martinelli, G., & Fabbri, F. (2022) · Cancers · doi:10.3390/cancers14102408 · Cited by 42
Therapeutic Vaccination for HPV-Mediated Cancers
Yan, F., Cowell, L. G., Tomkies, A., & Day, A. T. (2023) · Current Otorhinolaryngology Reports · doi:10.1007/s40136-023-00443-8 · Cited by 43
Spatial resolution of cellular senescence dynamics in human colorectal liver metastasis
Garbarino, O., Lambroia, L., Basso, G., Marrella, V., Franceschini, B., Soldani, C., Pasqualini, F., Giuliano, D., Costa, G., Peano, C., et al. (2023) · Aging Cell · doi:10.1111/acel.13853 · Cited by 43
“Additionally, understanding how targeting senescent cancer cells impacts tumoral immune microenvironment or how the immune system can be harmed to drive the clearance of bad SMCCs will be crucial to enroll senotherapies for clinical trials (Amor et al., 2020; Waldman et al., 2020).”
BackgroundAdditively manufactured Bi-functionalized bioceramics for reconstruction of bone tumor defects
Belluomo, R., Khodaei, A., & Yavari, S. A. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.08.042 · Cited by 42
Zhang, P., Li, Z., Cao, W., Tang, J., Xia, Y., Peng, L., & Ma, J. (2023) · Advanced Materials · doi:10.1002/adma.202305215 · Cited by 42
Yin, J., Gu, T., Chaudhry, N. Y., Davidson, N. E., & Huang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1325615 · Cited by 40
Sam, J., Höfer, T., Kuettel, C., Claus, C., Thom, J. T., Herter, S., Georges, G. J., Korfi, K., Lechmann, M., Eigenmann, M. J., et al. (2024) · Blood · doi:10.1182/blood.2023023381 · Cited by 42
Zhu, X., Huang, X., Hu, M., Sun, R., Li, J., Wang, H., Pan, X., Ma, Y., Ning, L., Tong, T., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.03.002 · Cited by 43
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
Middha, P., Thummalapalli, R., Betti, M. J., Yao, L., Quandt, Z., Balaratnam, K., Bejan, C. A., Cardenas, E. R., Falcon, C. J., Faleck, D. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44512-4 · Cited by 42
The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy
Abou‐El‐Enein, M. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0272 · Cited by 45
Genomic instability as a driver and suppressor of anti-tumor immunity
Requesens, M., Foijer, F., Nijman, H. W., & de Bruyn, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462496 · Cited by 45
Immune evasion in ovarian cancer: implications for immunotherapy and emerging treatments
Gupta, R., Kumar, R., Penn, C. A., & Wajapeyee, N. (2025) · Trends in Immunology · doi:10.1016/j.it.2024.12.006 · Cited by 46
Zhang, W., Hwang, J., Yadav, D., An, E., Kwak, M., Lee, P. C.-W., & Jin, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179125 · Cited by 42
The emerging potential ofmicrobiome transplantation on human health interventions
Junca, H., Pieper, D. H., & Medina, E. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.01.009 · Cited by 41
Hou, J., He, Z., Liu, T., Chen, D., Wang, B., Wen, Q., & Zheng, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.755053 · Cited by 48
Moutafi, M. K., Martínez-Morilla, S., Divakar, P., Vathiotis, I. A., Gavrielatou, N., Aung, T. N., Yaghoobi, V., Fernandez, A. I., Zugazagoitia, J., Herbst, R. S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.04.009 · Cited by 46
Song, J., Yang, R., Wei, R., Du, Y., He, P., & Liu, X. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00475-8 · Cited by 43
Epigenetic regulation of T cell adaptive immunity
Frias, A. B., Boi, S. K., Lan, X., & Youngblood, B. (2021) · Immunological Reviews · doi:10.1111/imr.12943 · Cited by 44
A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade
Ngoi, N. Y. L., Peng, G., & Yap, T. A. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-025136 · Cited by 42
Liang, J., Cheng, K., Li, Y., Xu, J., Chen, Y., Ma, N., Feng, Q., Zhu, F., Ma, X., Zhang, T., et al. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.11.032 · Cited by 42
Siddiqui, S., & Glauben, R. (2022) · Cancers · doi:10.3390/cancers14010250 · Cited by 41
Silva-Pilipich, N., Lasarte-Cía, A., Lozano, T., Martín-Otal, C., Lasarte, J. J., & Smerdou, C. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.020 · Cited by 41
The past, present, and future of chemotherapy with a focus on individualization of drug dosing
DeRidder, L. B., Rubinson, D. A., Langer, R., & Traverso, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.10.043 · Cited by 42
USP7 Inhibitors in Cancer Immunotherapy: Current Status and Perspective
Korenev, G., Yakukhnov, S., Druk, A., Golovina, A., Chasov, V. V., Mirgayazova, R., Ivanov, R. A., & Bulatov, E. (2022) · Cancers · doi:10.3390/cancers14225539 · Cited by 44
A Tandem‐Locked Fluorescent NETosis Reporter for the Prognosis Assessment of Cancer Immunotherapy
Cheng, P., He, S., Zhang, C., Liu, J., & Pu, K. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202301625 · Cited by 41
CircRNAs in tumor immunity and immunotherapy: Perspectives from innate and adaptive immunity
Yu, L., Xiao, Q., Yu, B., Lv, Q., Liu, Z., & Yin, J. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216219 · Cited by 41
Metastasis organotropism in colorectal cancer: advancing toward innovative therapies
He, K., Wang, Z., Luo, M., Li, B., Ding, N., Li, L., He, B., Wang, H., Cao, J., Huang, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04460-5 · Cited by 45
TEPCAM : Prediction of T ‐cell receptor–epitope binding specificity via interpretable deep learning
Chen, J., Zhao, B., Lin, S., Sun, H., Mao, X., Wang, M., Chu, Y., Hong, L., Wei, D., Li, M., et al. (2023) · Protein Science · doi:10.1002/pro.4841 · Cited by 40
Wold, C. W., CHRISTOPOULOS, P. F., Arias, M. A., Dzovor, D. E., Øynebråten, I., Corthay, A., & Inngjerdingen, K. T. (2024) · Communications Biology · doi:10.1038/s42003-024-05853-y · Cited by 41
Metabolic rewiring and communication in cancer immunity
Chapman, N. M., & Chi, H. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.001 · Cited by 44
Cisplatin in the era of PARP inhibitors and immunotherapy
Duan, M., Leng, S., & Mao, P. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108642 · Cited by 45
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia
Mazziotta, F., Biavati, L., Rimando, J. C., Rutella, S., Borcherding, N. C., Parbhoo, S., Mukhopadhyay, R., Chowdhury, S., Knaus, H. A., Valent, P., et al. (2024) · Blood · doi:10.1182/blood.2023021680 · Cited by 41
Nguyen, H. T., Kan, E. L., Humayun, M., Gurvich, N., Offeddu, G. S., Wan, Z., Coughlin, M. F., Renteria, D. C., Loew, A., Wilson, S. D., et al. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2024.122731 · Cited by 42
Biometallic ions and derivatives: a new direction for cancer immunotherapy
Zhao, L., Gui, Y., Cai, J., & Deng, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02225-w · Cited by 46
Wang, M., Bai, S., & Zhang, Y. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00502g · Cited by 42
Alistipes finegoldii augments the efficacy of immunotherapy against solid tumors
Wu, Z., Wu, Q., Han, Y., Xiang, S.-J., Wang, Y., Wu, W.-W., Chen, Y., Feng, Z., Wang, Y.-Y., Xu, Z.-G., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.07.002 · Cited by 46
Johnson, R. L., Cummings, M., Thangavelu, A., Theophilou, G., Jong, D. D., & Orsi, N. M. (2021) · Cancers · doi:10.3390/cancers13246231 · Cited by 39
Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
Bissonnette, F. S.-D., Khoury, R., Mediratta, K., El‐Sahli, S., Wang, L., & Lavoie, J. R. (2022) · Cancers · doi:10.3390/cancers14020451 · Cited by 41
Polyaniline-Based Glyco-Condensation on Au Nanoparticles Enhances Immunotherapy in Lung Cancer
Su, W., Chang, L.-C., Song, W.-H., Yang, L., Wang, L., Chia, Z., Chin, Y., Shan, Y.-S., Huang, C., & Yeh, C. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c03839 · Cited by 42
Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer
Janssen, J. B. E., Medema, J. P., Gootjes, E. C., Tauriello, D. V. F., & Verheul, H. M. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102433 · Cited by 42
Mencattini, A., Lansche, C., Veith, I., Erbs, P., Balloul, J., Quéméneur, É., Descroix, S., Mechta‐Grigoriou, F., Zalcman, G., Zaupa, C., et al. (2022) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2022.114571 · Cited by 41
Advancements in Cancer Immunotherapies
Roy, R., Singh, S. K., & Misra, S. (2022) · Vaccines · doi:10.3390/vaccines11010059 · Cited by 44
Won, J. E., Byeon, Y., Wi, T. I., Lee, C. M., Lee, J. H., Kang, T. H., Lee, J., Lee, Y., Park, Y., & Han, H. D. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003928 · Cited by 42
Salivary Gland Dysfunction Secondary to Cancer Treatment
Monreal, A. V., POLONSKY, G., Shiboski, C. H., Sankar, V., & Villa, A. (2022) · Frontiers in Oral Health · doi:10.3389/froh.2022.907778 · Cited by 42
Schmidt, F., Fields, H. F., Purwanti, Y. I., Milojkovic, A., Salim, S., Wu, K. X., Simoni, Y., Vitiello, A., MacLeod, D. T., Nardin, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113250 · Cited by 38
Liu, T., Si, X., Liu, L., Ma, S., Huang, Z., Zhang, Y. X., Song, W., Zhang, Y., & Chen, X. (2024) · ACS Nano · doi:10.1021/acsnano.3c08376 · Cited by 43
Ruggiu, M., Guérin, M. V., Corre, B., Bardou, M., Alonso, R., Russo, E., Garcia, Z., Feldmann, L., Lemaı̂tre, F., Dusséaux, M., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232104 · Cited by 42
Blüm, P., & Käyser, S. (2024) · Cancers · doi:10.3390/cancers16081599 · Cited by 42
Epithelial–mesenchymal plasticity in cancer: signaling pathways and therapeutic targets
Wang, X., Xue, X., Pang, M., Yu, L., Qian, J., Li, X., Tian, M., Lü, A., Lu, C. Y., & Liu, Y. (2024) · MedComm · doi:10.1002/mco2.659 · Cited by 45
Chen, Y., Lu, Y., Lei, H., Liu, L., Li, X., Yang, Y., Sun, S., Yu, Q., Wang, L., Wu, J., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c10378 · Cited by 42
Moonlighting Proteins Are Important Players in Cancer Immunology
Adamo, A., Frusteri, C., Pallotta, M. T., Pirali, T., Sartoris, S., & Ugel, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.613069 · Cited by 41
Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment
Gaggianesi, M., Franco, S. D., Pantina, V. D., Porcelli, G., D’Accardo, C., Verona, F., Veschi, V., Colarossi, L., Faldetta, N., Pistone, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702642 · Cited by 43
Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
Sobottka, B., Nowak, M., Frei, A. L., Haberecker, M., Merki, S., Levesque, M. P., Dummer, R., Moch, H., Koelzer, V. H., Aebersold, R. H., et al. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00653-y · Cited by 39
Karin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 41
Development of CAR T Cell Therapy in Children—A Comprehensive Overview
Boettcher, M., Joechner, A., Li, Z., Yang, S. F., & Schlegel, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11082158 · Cited by 42
Wanderley, C. W. S., Corrêa, T. S., Scaranti, M., Cunha, F. Q., & Barroso‐Sousa, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.816642 · Cited by 40
Nanosensitizer-assisted sonodynamic therapy for breast cancer
Yu, J., Hu, J.-R., Tian, Y., Lei, Y.-M., Hu, H.-M., Lei, B.-S., Zhang, G., Sun, Y., & Ye, H.-R. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03311-3 · Cited by 43
TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine
Li, G., Srinivasan, S., Wang, L., Ma, C., Guo, K., Xiao, W., Liao, W., Mishra, S., Zhang, X., Qiu, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33768-x · Cited by 40
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 42
Mullen, N. J., Shukla, S. K., Thakur, R. K., Kollala, S. S., Wang, D., Chaika, N. V., Santana, J. F., Miklavcic, W. R., LaBreck, D. A., Mallareddy, J. R., et al. (2023) · eLife · doi:10.7554/elife.87292 · Cited by 50
Jing, L., An, Y., Cai, T., Xiang, J., Li, B., Guo, J., Ma, X., Wei, L., Tian, Y., Cheng, X., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01047-4 · Cited by 39
DNA mismatch repair in cancer immunotherapy
Guan, J., & Li, G. (2023) · NAR Cancer · doi:10.1093/narcan/zcad031 · Cited by 41
STING agonist diABZI enhances the cytotoxicity of T cell towards cancer cells
Wang, L., Liang, Z., Guo, Y., Habimana, J. D. D., Ren, Y., Amissah, O. B., Mukama, O., Peng, S., Ding, X., Lv, L., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06638-1 · Cited by 42
Procoagulant platelets promote immune evasion in triple-negative breast cancer
Schaubächer, J. B., Smiljanov, B., Haring, F., Steiger, K., Wu, Z., Ugurluoglu, A., Luft, J., Ballke, S., Mahameed, S., Schneewind, V., et al. (2024) · Blood · doi:10.1182/blood.2023022928 · Cited by 40
Rad, H. F., Tahmasebi, H., Javani, S., Hemati, M., Zakerhamidi, D., Hosseini, M., Alibabaei, F., Banihashemian, S. Z., Oksenych, V., & Eslami, M. (2024) · Biomedicines · doi:10.3390/biomedicines12122776 · Cited by 43
Zhang, Y., Wang, N., Zhang, L., Zhuang, Y., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2025) · MedComm · doi:10.1002/mco2.70383 · Cited by 46
Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development
Grzywa, T. M., Justyniarska, M., Nowis, D., & Gołąb, J. (2021) · Cancers · doi:10.3390/cancers13040870 · Cited by 41
Manukian, G., Kivolowitz, C., DeAngelis, T., Shastri, A. A., Savage, J. E., Camphausen, K. A., Rodeck, U., Zarif, J. C., & Simone, N. L. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.02.029 · Cited by 39
Melo, C. M., Vidotto, T., Chaves, L. P., Lautert-Dutra, W., dos Reis, R. B., & Squire, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179550 · Cited by 42
CAR-T cells, from principle to clinical applications
Bourbon, E., Ghesquières, H., & Bachy, E. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.02.017 · Cited by 40
Sung, J., & Cheong, J. (2022) · Cells · doi:10.3390/cells11050768 · Cited by 40
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question
Ordóñez‐Reyes, C., García-Robledo, J. E., Chamorro, D. F., Mosquera, A., Sussmann, L., Ruíz-Patiño, A., Arrieta, O. G., Zatarain-Barrón, L., Rojas, L., Russo, A., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061243 · Cited by 41
Uceda-Castro, R., Margarido, A. S., Cornet, L., Vegna, S., Hahn, K., Song, J., Putavet, D. A., van Geldorp, M., Çitirikkaya, C. H., de Keizer, P. L. J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100821 · Cited by 40
Metadata
- Authors
- Waldman, A. D., Fritz, J. M., & Lenardo, M. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lenardo, Michael J.
- Venue
- Nature Reviews Immunology
- Published
- 2020-05-20
- Volume
- 20
- Issue
- 11
- Pages
- 651-668
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7238960
- OpenAlex
- W3028523516
- Cited by
- 4,154
- References
- 302
- Citations by year
- 2026: 382 · 2025: 748 · 2024: 867 · 2023: 824 · 2022: 754 · 2021: 511 · 2020: 59
- FWCI
- 58.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Emory University
- National Institutes of Health
- National Institute of General Medical Sciences (T32GM008169)
- National Institute of Allergy and Infectious Diseases
- NHLBI Division of Intramural Research
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cancer immunotherapy, T cells, T cell regulation, immune checkpoint blockade, adoptive cellular therapy, clinical trials, immunotherapy toxicity, history of cancer immunotherapy
- MeSH terms
- Immune Checkpoint Inhibitors, Animals, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Immunotherapy, Adoptive, Cancer Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
